Jinhan Xie
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.
Journal: British journal of haematology
Published: August 14, 2025
High-throughput 3D engineered paediatric tumour models for precision medicine.
Journal: Molecular systems biology
Published: August 13, 2025
Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.
Journal: Molecular cancer therapeutics
Published: July 01, 2025
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.
Journal: Molecular cancer therapeutics
Published: July 01, 2025
Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy.
Journal: Cancer research communications
Published: February 07, 2025
Working with Miraculous Mice: Mus musculus as a Model Organism.
Journal: Current protocols
Published: October 22, 2024
Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
Journal: British journal of haematology
Published: September 26, 2024
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
Journal: Blood cancer journal
Published: September 08, 2024
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.
Journal: Cancer research
Published: November 28, 2022
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.
Journal: EMBO molecular medicine
Published: May 28, 2021
The important role of routine cytopathology in pediatric precision oncology.
Journal: Cancer cytopathology
Published: March 15, 2021
CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Journal: British journal of cancer
Published: February 01, 2020
Last Updated: 09/26/2026